Acasti Pharma Inc (TSX-V:ACST, NASDAQ:ACST). CEO Jan D’Alvise joined Proactive New York to discuss the Laval, Québec-based group's recent acquisition of Grace Therapeutics including its therapeutic pipeline consisting of three clinical stage and pre-clinical stage assets.
D’Alvise walked through each, noting the group is 'very well funded' having raised $60 million earlier in 2021, with enough cash to 'completely finish' the program for its lead compound GTX-104 and 'significantly expand' its two other compounds.